B2DB — Who said what, where, and when

Philip Scheltens

EQT Life Sciences

Philip Scheltens is listed as EQT Life Sciences. Philip is scheduled to speak at AD/PD 2027 – Advances in Science & Therapy on 17 March 2027.

Compiled from published conference agendas; not yet confirmed by Philip. Is this you? Claim this profile.

About

Prof. dr. Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD in 1993. He was appointed as Professor of Cognitive Neurology in 2000 and founded the Alzheimer Center at Amsterdam University Medical Centers in that same year, which he directed until 2022. Currently he is partner at EQT group and heads the Dementia Fund at EQT Life Sciences, that he started in 2020. He has been the (inter)national PI for over 35 studies, including phase 1-3 multicenter clinical trials. He supervised >100 PhD theses since 2000. He founded and led the Dutch National Plan against dementia and served as chair of the board until 2021 and was on the advisory panel of the Dutch National Strategy for Dementia until 2025. Philip served as co-editor-in-chief of Alzheimer’s Research & Therapy from 2013-2022 and co-led various EU projects. He authored over 1200 peer reviewed papers and > 75 book chapters and co-edited several major textbooks. He is member of

Upcoming

AD/PD 2027 – Advances in Science & Therapy 16 March 2027 – 20 March 2027